Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling studyResearch in context
Summary: Background: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation....
Сохранить в:
Главные авторы: | , , , , , , , , , , , , |
---|---|
Формат: | |
Опубликовано: |
Elsevier,
2023-08-01T00:00:00Z.
|
Предметы: | |
Online-ссылка: | Connect to this object online. |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Копировать 1 | Доступно |